Paris-based BrainTale, a medtech company that develops and distributes diagnosis and prognosis tools that decipher white matter to enable better brain care, announced on Tuesday that it has secured €4.5M in a fresh round of funding.
Prof. Louis Puybasset, chairman of the scientific advisory board and co-founder of BrainTale, says, “After 15 years of academic research and 5 years of investment, the solutions developed by BrainTale are finally available to patients and my colleagues.”
“Responding to the unmet medical need that has been the driving force behind this ambitious project since its inception is one of the major challenges of the coming years, and BrainTale’s development is perfectly in line with this dynamic,” adds Prof. Puybasset.
BrainTale aims to provide physicians and pharma companies with solutions to improve the diagnosis, monitoring and prediction of neurological diseases and disorders, in particular, Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis and traumatic brain injury.
The company says it will use the funds to accelerate its development in Europe and the US.
Currently, the company’s customers in Europe include hospitals (Paris Region Greater Hospitals, Hôpitaux Universitaires de Strasbourg) and biotech (Minoryx), as well as partners in the US (Massachusetts General Hospital – Harvard).
Julie Rachline, president of LallianSe and CEO of BrainTale, says, “The commitment of Capital Grand Est and MACSF by our side reinforces our strategy to establish BrainTale’s brain measurement as a reference, in particular, to enable drug developers to accelerate the development of new therapies in a more agile and efficient way, bringing a new dynamic in neurosciences.”
“Deciphering the Brain tale”
Founded in 2018, BrainTale is deciphering white matter to enable better brain care with clinically validated prognostic solutions.
It offers a digital biomarkers platform to help in decision-making by measuring white matter microstructure abnormalities in a non-invasive, sensitive, and reliable manner.
BrainTale claims to make it possible to identify at-risk individuals, make an early diagnosis, track the course of a disease, and evaluate the efficacy of neurology therapies.
The company’s products are produced based on more than 15 years of research and development to satisfy the medical requirements and standards of healthcare experts for the benefit of patients.
The platform’s goal is also to assist pharmaceutical companies in the development of new drugs.
BrainTale’s biomarkers, which can distinguish between active and placebo groups in clinical trials and support treatment efficacy demonstration, were developed to correlate with conventional clinical scores.
Some demyelinating illnesses, like adrenoleukodystrophy (ALD), have previously shown the promise of BrainTale biomarkers.
The French company was co-founded by Prof. Louis Puybasset (Intensivist, Paris Region Greater Hospitals, Paris), Damien Galanaud (Neuroradiologist, Paris Region Greater Hospitals, Paris), Lionel Velly (Intensivist, Hôpital de la Timone, Marseille Hospitals, Marseille), Didier Cassereau (Research Professor, ESPCI), Vincent Perlbarg (Engineer and PhD in Medical Physics), and LallianSe, the life sciences integrator.